Neoadjuvant therapy (NAT) is the preferred treatment for HER2 overexpressing breast cancer, resulting in significantly higher rates of pathologic complete remission (pCR), along with extended disease-free survival (DFS) and overall survival (OS), leading to improved prognosis (5–7). This evidence concerns the gene ERBB2 and breast cancer.